Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...
The benefits of limiting dual antiplatelet therapy (DAPT) to a short course after PCI for acute coronary syndromes vary depending on the type of monotherapy used afterward, according to a new network ...
Amsterdam, Netherlands – 28 Aug 2023: Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischaemic events in acute coronary ...
Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients who’ve undergone PCI seems to reduce MACCE compared with aspirin monotherapy ...
Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high risk for ...
An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results